Dose-response relationships of chronic adriamycin toxicity in rabbits.

Doxorubicin was administered chronically to 55 female New Zealand White rabbits in order to determine a chronic dose-response relationship for doxorubicin-induced cardiomyopathy, skeletal myopathy and nephropathy. Systolic time interval recording as a measure of cardiac function in doxorubicin-induced cardiomyopathy in the rabbit is compared to histologic grading of the cardiomyopathy. Histologic evidence of cardiomyopathy was not seen at cumulative doses less than 100 mg/m2 but incidence and severity of cardiomyopathy increased with increasing doxorubicin dosage.

Systolic time interval recordings in rabbits with congestive cardiomyopathy induced by chronic anthracycline administration.

Systolic time interval recordings were performed serially on 104 healthy female New Zealand White rabbits and 51 rabbits with congestive heart failure (CHF) induced by chronic anthracycline drug therapy. The results were analyzed and the comparisons were made with studies of systolic time interval recordings of CHF in persons. In the rabbit, CHF is manifested by prolongation of the isovolumic contraction time, the preejection period (PEP), and by shortening of the left ventricular ejection time (LVET).

Systolic time interval recordings as a measure of cardiac function in the healthy rabbit: reference values.

Results of systolic time interval recordings obtained serially on 104 female New Zealand White rabbits were analyzed for reproducibility, variation with respect to changes in heart rate (HR), and interrelationship of the various systolic time intervals. A table of values for systolic time intervals in the healthy rabbit was constructed. The preejection period (PEP), left ventricular ejection time (LVET), and PEP/LVET ratio were 0.

Comparison of methyl-CCNU and CCNU in patients with advanced forms of Hodgkin's disease, lymphosarcoma nad reticulum cell sarcoma.

In May 1972, the Cancer and Leukemia Group B initiated a randomized study comparing the effectiveness of CCNU and methyl-CCNU in patients with advanced malignant lymphomas, including Hodgkin's disease (HD), lymphosarcoma (LYS) and reticulum cell sarcoma (RCS). A single dose of 100 mg/m2 of CCNU or 150 mg/m2 of methyl-CCNU was given orally every 6 weeks. In patients with leukopenia or thrombocytopenia, due to prior treatment, this dose was reduced to 70 mg/m2 of CCNU and 100 gm/m2 of methyl-CCNU.